President Donald Trump's administration has placed a freeze on information being released from government health agencies.

Using glucocorticoids, rituzimab, or certain immunosuppressants to treat connective tissue diseases is associated with greater risks for severe COVID-19-related outcomes.

Linzagolix with and without concomitant add-back therapy was associated with reductions in heavy menstrual bleeding in uterine fibroids.

Adiponectin levels were associated with increased likelihood of metabolic health improvements and lower risk for diabetes across 6 years.

The ACS has released cancer statistics for 2025 suggesting that more than 2 million new cases of cancer will be diagnosed in the US this year.

There is considerable uncertainty regarding the effects of puberty blockers in young individuals experiencing gender dysphoria (GD).

The FDA has accepted the application for belzutifan for advanced, unresectable, or metastatic pheochromocytoma and paraganglioma.

For patients with type 1 diabetes with moderate-to-severe gastrointestinal symptoms, fecal microbiota transplantation (FMT) is safe and improves clinical outcomes.

A scientific statement regarding nursing wellness in cardiovascular and stroke care has been published by the American Heart Association.

Thyroid cancer recurrence risk was not elevated among patients with high-normal vs low-normal exposure to TSH following thyroidectomy.

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

In the first 22 months of a mavacamten REMS program, few patients needed a temporary interruption in treatment for LVEF below 50%.